Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR: Macitentan for RV Remodeling in PAH
NCT02310672Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 4, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Right Ventricular Stroke Volume at 26 weeks and Pulmonary Vascular Resistance at 26 weeks. Started Jun 2015; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02310672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310672.